{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":18,"n_cols":5,"rows_kept":18,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[12,2,12,3],[13,2,13,3],[16,2,16,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910781003703321"]
[null,null,"Autore",null,"Hanson Sarah"]
[null,null,"Titolo",null,"CNS clinical trials [[electronic resource] ] : suicidality and data collection : workshop summary / / Sarah Hanson, Miriam Davis, and Bruce Altevogt ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy"]
[null,null,"Pubbl/distr/stampa",null,"Washington, D.C., : National Academies Press, 2010"]
[null,null,"ISBN",null,"0-309-18648-X"]
[{"$nulls":4},"1-282-97591-9"]
[{"$nulls":4},"9786612975912"]
[{"$nulls":4},"0-309-14884-7"]
[null,null,"Descrizione fisica",null,"xii, 75 p"]
[null,null,"Disciplina",null,"616.85/8445"]
[null,null,"Soggetti",null,"Suicide - Risk factors"]
[{"$nulls":4},"Suicide - Prevention"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Bibliographic Level Mode of Issuance: Monograph"]
[null,null,"Nota di contenuto",null,"Perspectives from the FDA, academia, and patients -- Data collection and optimization -- Data analysis -- Partnerships, opportunities, collaboration."]
[null,null,null,"Sommario/riassunto","\"The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.\"--Publisher's description."]